ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2018, 'Patients' Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'WORLD-FIRST IDENTIFICATION OF CIRCULATING PANCREATIC STELLATE CELLS IN METASTATIC PANCREATIC CANCER', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S114 - S114, presented at Annual Meeting of the American-Society-for-Gastrointestinal-Endoscopy / Digestive Disease Week, DC, Washington, 02 June 2018 - 05 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000450011100327&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Microscopic Surgical Margins and Outcome in Localized GIST Treated within the Eortc Stbsg, Agitg, Unicancer, Fsg, Isg and Geis Randomized Trial On Adjuvant Imatinib', in ANNALS OF SURGICAL ONCOLOGY, SPRINGER, IL, Chicago, pp. S6 - S6, presented at 71st Annual Cancer Symposium of the Society-of-Surgical-Oncology, IL, Chicago, 21 March 2018 - 24 March 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000431188600002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Establishment of a noval adjuvant model of orthotopic pancreatic cancer: effects of HGF-cMET inhibition on disease progression', Sydney, presented at Avner Cancer Symposium, Sydney
,2018, 'Inhbition of hepatocyte growth factor (HGF) signalling pathway in combination with chemotherapy reduces tumour buden in an orthotopic pancreatic cancer model', Sydney, presented at Avner Cancer Symposium, Sydney
,2017, 'Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 138 - 139, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Chemotherapy-Induced Peripheral Neuropathy - Patient Reported Outcomes Compared With Clinician and Nursing Assessment', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 183 - 184, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Circulating Pancreatic Stellate Cells (Cpscs) and Tumor Cells (Ctcs) in Metastatic Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1425 - 1425, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000414520800188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'The Effects of Exercise Training on Neurophysiology, Symptoms, and Function in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 130 - 131, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Circulating tumor and stellate cells in pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100112&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'How Long Have I Got? Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 76 - 76, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427542700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Stromal reprogramming offers a novel therapeutic approach in pancreatic cancer: Implications of targeting HGF/c-MET pathway', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)', in Annals of Oncology, pp. iii136, http://dx.doi.org/10.1093/annonc/mdx261.379
,2017, 'Exercise Induced Analgesia in Survivors of Cancer', in MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, CO, Denver, pp. 163 - 163, presented at Annual Meeting of the American-College-of-Sports-Medicine (ACSM), CO, Denver, 30 May 2017 - 03 June 2017, http://dx.doi.org/10.1249/01.mss.0000517274.66389.d8
,2016, 'CURRENT CLINICIAN PRACTICES IN UTILIZING RADIOTHERAPY AND MOLECULARLY TARGETED THERAPIES IN TREATING PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: AN ANZUP SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'Stromal remodeling in pancreatic cancer', in Pancreatology, Elsevier, Sendai, pp. S28 - S28, presented at International Association of Pancreatology, Sendai, -
,2015, 'SECOND-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE SERIES', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800296&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Synergistic effect of targeting EGFR and metabolism in sarcoma cell lines', Brisbane, Australia, presented at 2015 Annual Sarcoma Conference, Brisbane, Australia, 17 October 2015 - 18 October 2015
,2015, 'FIRST-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: AN AUSTRALIAN EXPERIENCE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Having cancer in a country not your own: the Chinese immigrant story in Australia', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358255000039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036902066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2015, 'The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care', in NEUROENDOCRINOLOGY, KARGER, SPAIN, Barcelona, pp. 98 - 98, presented at 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, SPAIN, Barcelona, 11 March 2015 - 13 March 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361683500062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Pancreatic cancer: stromal reprogramming offers a novel therapeutic approach', San Diego, Pancreas 44(8):1407, presented at American Pancreatic Association, San Diego, Pancreas 44(8):1407, -
,2015, 'Pancreatic cancer: stromal reprogramming offers a novel therapeutic approach', Shanghai, Pancreatology, presented at International Association of Pancreatology, Shanghai, Pancreatology, -
,2015, 'Pancreatic cancer: stromal reprogramming offers a novel therapeutic approach', Toledo, Pancreatology 15(3):S17, presented at European Pancreatic Club, Toledo, Pancreatology 15(3):S17, -
,2014, 'THE COLON HEALTH AND LIFE-LONG EXERCISE CHANGE (CHALLENGE) TRIAL: PARTICIPANT ADHERENCE TO FITNESS ASSESSMENTS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 200 - 200, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900370&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Design and Synthesis of Novel PEGylated Star Nanoparticles as Delivery Agents for Short-Interfering RNA (siRNA) to Pancreatic Cancer Cells', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1416 - 1416, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344362600356&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Heat shock protein 47 is a potential therapeutic target for the depletion of cancer-promoting stromal cells in pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 7 - 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'A MULTI-CENTRE, PHASE II, OPEN-LABEL, SINGLE ARM STUDY OF PANITUMUMAB, CISPLATIN AND GEMCITABINE IN BILIARY TRACT CANCER: PRIMARY RESULTS OF THE AGITG TACTIC STUDY', in Annals of Oncology, Oxford University Press (OUP), Madrid, Spain, pp. 1 - 1, presented at 39th ESMO Congress (ESMO 2014), Madrid, Spain, 26 September 2014 - 30 September 2014, http://dx.doi.org/10.1093/annonc/mdu334.106
,2014, 'Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.9537
,2014, 'Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.428
,2014, 'EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.438
,2014, 'Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Gastrointestinal Cancers Symposium, CA, San Francisco, 16 January 2014 - 18 January 2014, http://dx.doi.org/10.1200/jco.2014.32.3_suppl.228
,2014, 'CURRENT CLINICIAN PRACTICES IN UTILISING RADIOTHERAPY AND TARGETED THERAPIES IN TREATING PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - A SURVEY OF AUSTRALIAN AND NEW ZEALAND CLINICIANS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716200043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Stereotactic body radiotherapy using 4D image-guidance for inoperable primary liver cancer or metastases', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, pp. S124 - S125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687118700358&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Hepatocyte Growth Factor (HGF) inhibition may be a superior therapeutic approach than gemcitabine in pancreatic cancer', Melbourne, presented at Australasian Pancreatic Club and the Australian Health and Medical Research Congress, Melbourne, -
,2014, 'The role of hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: anti-angiogenic implications in pancreatic cancer', Southampton, Pancreatology 14(3):S9, presented at International Association of Pancreatology and European Pancreatic Club, Southampton, Pancreatology 14(3):S9, -
,2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'beta III-Tubulin is a Novel Therapeutic Target for the Treatment of Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1381 - 1381, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330468400204&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Inhibition of beta III-Tubulin Using a Novel Nanoparticle-siRNA Approach Sensitizes Pancreatic Cancer Cells to Chemotherapy', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1385 - 1385, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330468400222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'IS SECOND LINE CHEMOTHERAPY IN PANCREATIC CANCER ONE LINE TOO MANY?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 150 - 150, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PANCREATIC CANCER PATIENT'S MODERATE OR HIGH UNMET SUPPORTIVE CARE NEEDS OVER TIME AND RISK FACTORS OF FUTURE UNMET NEEDS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 105 - 105, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800145&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Therapeutic Potential of Angiogenesis Inhibitors for Gastric Cancer', in Annals of Oncology, pp. ix8, http://dx.doi.org/10.1093/annonc/mdt437.1
,2013, 'Hepatocyte Growth Factor Inhibition: A Therapeutic Approach Superior to Gemcitabine in Pancreatic Cancer?', in Pancreas, Lippincott Williams & Wilkins, Miami, pp. 1377 - 1377, presented at American Pancreatic Association, Miami, 31 October 2013 - 02 November 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000330468400188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'beta III-tubulin is a novel therapeutic target for the treatment of pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 12 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S614 - S614, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Evaluation of peripheral neuropathy in a phase Ill trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S613 - S613, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Positron emission tomography (PET) response from a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients (pts) with metastatic adenocarcinoma of the pancreas', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S611 - S611, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'What do patients really mean when they complain of fatigue after treatment? Reliable identification of post cancer fatigue', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S283 - S283, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843602060&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419601432&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,